$BMRN

AI Analysis

Generated on May 11, 2026

AI Score
68/ 100
Hold$BMRN

BioMarin Pharmaceutical

$BMRNNASDAQHealthcareLarge-Cap

BioMarin develops treatments for rare diseases including Voxzogo for achondroplasia and enzyme replacement therapies.

Market Cap
$14.0B
Revenue (TTM)
$2.7B
+12.0%
Net Income (TTM)
$0.4B
+25.0%
EPS (TTM)
$2.00
P/E Ratio
32.0
Dividend Yield
0.0%
52-Week Range
$65-$100
Beta
0.52
Dimension Scores
Fundamental
64
Technical
64
Sentiment
72
Risk / Reward
64
Momentum
72
FundTechSentRiskMome
Financial Health
Profitability
69moderate
Growth
75strong
Liquidity
72strong
Solvency
66strong
Efficiency
62moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $BMRN

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.